CryoCath tests new use for cryoablation system:
This article was originally published in Clinica
Executive Summary
CryoCath Technologies has enrolled nine patients in a US study to assess a new clinical application for its Freezor cryoablation system. As an extension of the company's completed pivotal FROSTY trial, the new study will evaluate cryoablating, through the coronary venous system, a specific arrhythmia that the firm said was historically very difficult to treat with existing radiofrequency technology - epicardial posteroseptal accessory AV pathway. Data from the study will be added to the Montreal, Quebec firm's PMA application as part of the FDA review process to approve the Freezor system for the US market. CryoCath believes that the system will become commercially available in 2003.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.